Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results.
Anti-Inflammatory Agents
/ adverse effects
Betacoronavirus
/ drug effects
COVID-19
Coronavirus Infections
/ drug therapy
Critical Care
Female
Hospital Mortality
Humans
Hydroxychloroquine
/ adverse effects
Intensive Care Units
Length of Stay
/ statistics & numerical data
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ drug therapy
Preliminary Data
Retrospective Studies
SARS-CoV-2
Viral Load
/ drug effects
COVID-19 Drug Treatment
Covid-19 pneumonia
Hydroxychloroquine
Intensive care unit
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
29
04
2020
revised:
29
07
2020
accepted:
31
07
2020
pubmed:
11
8
2020
medline:
27
10
2020
entrez:
11
8
2020
Statut:
ppublish
Résumé
During the Covid-19 pandemic, many intensive care unit (ICU) patients received hydroxychloroquine. The primary objective of this study was to assess the effects of hydroxychloroquine according to its plasma concentration in ICU patients. A single-center retrospective study was performed from March to April 2020 in an ICU of a university hospital. All patients admitted to the ICU with confirmed Covid-19 pneumonia and treated with hydroxychloroquine were included. The study compared 17 patients in whom the hydroxychloroquine plasma concentration was in the therapeutic target (on-target) and 12 patients in whom the plasma concentration was below the target (off-target). The follow-up of patients was 15 days. No association was found between hydroxychloroquine plasma concentration and viral load evolution (P = 0.77). There was no significant difference between the two groups for duration of mechanical ventilation, length of ICU stay, in-hospital mortality, and 15-days mortality. These findings indicate that hydroxychloroquine administration for Covid-19 patients hospitalized in ICU is not associated with improved outcomes. Larger multicenter studies are needed to confirm these results.
Identifiants
pubmed: 32777263
pii: S0924-8579(20)30327-7
doi: 10.1016/j.ijantimicag.2020.106136
pmc: PMC7413851
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
106136Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
J Antimicrob Chemother. 2015;70(6):1608-21
pubmed: 25693996
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
JAMA Cardiol. 2020 Sep 1;5(9):1067-1069
pubmed: 32936266
JAMA Netw Open. 2020 Apr 24;3(4):e208857
pubmed: 32330277
Clin Infect Dis. 2019 Jun 18;69(1):52-58
pubmed: 30304487
Clin Infect Dis. 2020 Apr 07;:
pubmed: 32255489
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Crit Care. 2020 Jul 11;24(1):418
pubmed: 32653015
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Intensive Care Med. 2020 Apr;46(4):579-582
pubmed: 32103284
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204